Ayble Health lands $16M Series A to expand AI-driven digestive care
What's the deal? Ayble HealthDealroom has a profile for this one. Try Dealroom →, a virtual multidisciplinary gastrointestinal clinic, has raised US$10.4M Series A led by NeonDealroom has a profile for this one. Try Dealroom →. Unum VenturesDealroom has a profile for this one. Try Dealroom →, Upfront Ventures, M13Dealroom has a profile for this one. Try Dealroom →, Cleveland Clinic Ventures, DigiTxDealroom has a profile for this one. Try Dealroom →, and Accomplice also joined the oversubscribed round.
The Boston-based company said the raise brings its total capital to over $27 million.
What's the endgame? Ayble will use the money to advance its AI-plus-clinician care model, deepening personalisation in patient enrollment and care delivery. It also plans to expand beyond gastrointestinal (GI) care into adjacent areas, starting with autoimmune conditions.
Why now? The two categories are clinically linked. A 2025 study of more than 141 million patients found inflammatory bowel disease associated with 24 distinct autoimmune comorbidities.
"Many patients are also managing autoimmune conditions, and too often, no one is treating the whole picture," said founder and chief executive officer Sam Jactel, who has IBD himself.
By the numbers: GI conditions affect more than 70 million Americans and drive $136 billion in annual US healthcare spending — more than diabetes or heart disease. Yet nearly 70% of US counties lack a single practising gastroenterologist, and patients wait an average of 40 days for an in-person specialty visit.
Unprecedented scale: Ayble is now in-network with most commercial health plans and covers over 80 million Americans through payer, employer, and health system partnerships. The company was recently nominated for the Galien Prize, an award widely regarded as a top honour in biomedical innovation.
The signal: GI conditions rank as a top-five driver of medical claims and one of the fastest-growing cost centres across commercially insured populations. That escalating burden — echoed by rising autoimmune costs — explains why investors are backing virtual clinics built to treat overlapping chronic conditions together.
Image credit: Ayble Health
